Patient Factors Influencing the Prescribing of Lipid Lowering Drugs for Primary Prevention of Cardiovascular Disease in UK General Practice: A National Retrospective Cohort Study

被引:46
|
作者
Wu, Jianhua [1 ]
Zhu, Shihua [2 ]
Yao, Guiqing Lily [3 ]
Mohammed, Mohammed A. [2 ]
Marshall, Tom [2 ]
机构
[1] Univ London, Ctr Environm & Prevent Med, Barts & London Sch Med & Dent, London, England
[2] Univ Birmingham, Sch Publ Hlth & Populat Sci, Birmingham, W Midlands, England
[3] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England
来源
PLOS ONE | 2013年 / 8卷 / 07期
关键词
CORONARY-HEART-DISEASE; MULTIVARIATE PREDICTION; EUROPEAN GUIDELINES; HEALTH-CARE; CHOLESTEROL; RISK; HYPERCHOLESTEROLEMIA; UNDERTREATMENT; POPULATION; MANAGEMENT;
D O I
10.1371/journal.pone.0067611
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Guidelines indicate eligibility for lipid lowering drugs, but it is not known to what extent GPs' follow guidelines in routine clinical practice or whether additional clinical factors systematically influence their prescribing decisions. Methods: A retrospective cohort analysis was undertaken using electronic primary care records from 421 UK general practices. At baseline (May 2008) patients were aged 30 to 74 years, free from cardiovascular disease and not taking lipid lowering drugs. The outcome was prescription of a lipid lowering drug within the next two years. The proportions of eligible and ineligible patients prescribed lipid lowering drugs were reported and multivariable logistic regression models were used to investigate associations between age, sex, cardiovascular risk factors and prescribing. Results: Of 365,718 patients with complete data, 13.8% (50,558) were prescribed lipid lowering drugs: 28.5% (21,101/74,137) of those eligible and 10.1% (29,457/291,581) of those ineligible. Only 41.7% (21,101/50,558) of those prescribed lipid lowering drugs were eligible. In multivariable analysis prescribing was most strongly associated with increasing age (OR for age >= 65 years 4.21; 95% CI 4.05-4.39); diabetes (OR 4.49; 95% CI 4.35-4.64); total cholesterol level >= 7 mmol/L (OR 2.20; 95% CI 2.12-2.29); and >= 4 blood pressure measurements in the past year (OR 4.24; 95% CI 4.06-4.42). The predictors were similar in eligible and ineligible patients. Conclusions: Most lipid lowering drugs for primary prevention are prescribed to ineligible patients. There is underuse of lipid lowering drugs in eligible patients.
引用
下载
收藏
页数:10
相关论文
共 50 条
  • [41] The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study
    Currie, Olivia
    Mangin, Dee
    Williman, Jonathan
    McKinnon-Gee, Bianca
    Bridgford, Paul
    BMJ OPEN, 2013, 3 (11):
  • [42] Mortality Rates and Causes of Death in Children with Epilepsy Prescribed Antiepileptic Drugs A Retrospective Cohort Study using the UK General Practice Research Database
    Ackers, Ruth
    Besag, Frank M. C.
    Hughes, Elaine
    Squier, Waney
    Murray, Macey L.
    Wong, Ian C. K.
    DRUG SAFETY, 2011, 34 (05) : 403 - 413
  • [43] Chronic obstructive pulmonary disease hospital admissions and drugs-unexpected positive associations: a retrospective general practice cohort study
    Harries, Timothy H.
    Seed, Paul T.
    Jones, Simon
    Schofield, Peter
    White, Patrick
    NPJ PRIMARY CARE RESPIRATORY MEDICINE, 2014, 24
  • [44] A retrospective cohort study assessing patient characteristics and the incidence of cardiovascular disease using linked routine primary and secondary care data
    Payne, Rupert A.
    Abel, Gary A.
    Simpson, Colin R.
    BMJ OPEN, 2012, 2 (02):
  • [45] Blood pressure monitoring and control by cardiovascular disease status in UK primary care: 10 year retrospective cohort study 1998-2007
    Laverty, Anthony A.
    Bottle, Alex
    Majeed, Azeem
    Millett, Christopher
    JOURNAL OF PUBLIC HEALTH, 2011, 33 (02) : 302 - 309
  • [46] A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus
    Abushanab, Dina
    Al-Badriyeh, Daoud
    Marquina, Clara
    Bailey, Cate
    Jaam, Myriam
    Liew, Danny
    Ademi, Zanfina
    CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (08)
  • [47] Patient and practice factors associated with HbA1c testing frequency in patients with type 2 diabetes: a retrospective cohort study in Australian general practice
    Imai, Chisato 'Chrissy'
    Li, Ling
    Hardie, Rae-Anne
    Pearce, Christopher
    Georgiou, Andrew
    AUSTRALIAN JOURNAL OF PRIMARY HEALTH, 2023, 29 (05) : 520 - 526
  • [48] Risk factors for primary prevention of cardiovascular disease and risk reduction by lipid control: the OMEGA study risk factor sub-analysis
    Teramoto, Tamio
    Kawamori, Ryuzo
    Miyazaki, Shigeru
    Teramukai, Satoshi
    Mori, Yoshihiro
    Okuda, Yasuyuki
    Hiramatsu, Katsutoshi
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2014, 36 (04) : 236 - 243
  • [49] Knowledge of cardiovascular disease risk factors and practice of primary prevention of cardiovascular disease by Community Pharmacists in Nigeria: a cross-sectional study (vol 40, pg 1587, 2018)
    Amadi, Casmir E.
    Lawal, Folasade O.
    Mbakwem, Amam C.
    Ajuluchukwu, Jayne N.
    Oke, David A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (01) : 293 - 293
  • [50] Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study
    Hideyuki Sawada
    Tomoko Oeda
    Kenji Yamamoto
    Atsushi Umemura
    Satoshi Tomita
    Ryutaro Hayashi
    Masayuki Kohsaka
    Takashi Kawamura
    BMC Neurology, 13